Spyre Therapeutics Inc. (SYRE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Spyre Therapeutics Inc. stock (SYRE) is currently trading at $45.68. Spyre Therapeutics Inc. PS ratio (Price-to-Sales) is 650.22. Analyst consensus price target for SYRE is $60.79. WallStSmart rates SYRE as Sell.
- SYRE PE ratio analysis and historical PE chart
- SYRE PS ratio (Price-to-Sales) history and trend
- SYRE intrinsic value — DCF, Graham Number, EPV models
- SYRE stock price prediction 2025 2026 2027 2028 2029 2030
- SYRE fair value vs current price
- SYRE insider transactions and insider buying
- Is SYRE undervalued or overvalued?
- Spyre Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- SYRE Piotroski F-Score and Altman Z-Score
- SYRE analyst price target and Smart Rating
Spyre Therapeutics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Spyre Therapeutics Inc. (SYRE) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Spyre Therapeutics Inc. (SYRE) Key Strengths (2)
104.69% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Spyre Therapeutics Inc. (SYRE) Areas to Watch (4)
Company is destroying shareholder value
Earnings declining -99.70%, profits shrinking
Very expensive at 650.2x annual revenue
Very expensive at 5.8x book value
Supporting Valuation Data
Spyre Therapeutics Inc. (SYRE) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.5/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Price/Sales. Some valuation metrics including Price/Sales (650.22), Price/Book (5.79) suggest expensive pricing. Growth concerns include EPS Growth at -99.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -25.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -25.20% needing improvement to support the investment thesis. Third, growth sustainability, with EPS Growth at -99.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SYRE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SYRE's Price-to-Sales ratio of 650.22x sits near its historical average of 595.01x (73th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 83% below its historical high of 3825.06x set in Feb 2026, and 37269% above its historical low of 1.74x in Jul 2022. Over the past 12 months, the PS ratio has compressed from ~1590.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Spyre Therapeutics Inc. (SYRE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Spyre Therapeutics Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -45M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.12, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Spyre Therapeutics Inc..
Bottom Line
Spyre Therapeutics Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Spyre Therapeutics Inc.(SYRE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.